| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/25/2011 | CA2789337A1 Hsa-related compositions and methods of use |
| 08/25/2011 | CA2784211A1 Neuregulin antagonists and use thereof in treating cancer |
| 08/24/2011 | EP2360260A1 BASB006 polynucleotide(s) and polypeptides from Neisseria meningitis |
| 08/24/2011 | EP2360257A2 Hepatitis B virus (HBV) variants |
| 08/24/2011 | EP2360254A1 Assays for screening anti-pd-1 antibodies and uses thereof |
| 08/24/2011 | EP2360252A1 Immunostimulatory nucleic acid molecules comprising GTCGTT motifs |
| 08/24/2011 | EP2360243A1 Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same |
| 08/24/2011 | EP2360187A1 Antibodies against HER2 truncated variant CTF-611 |
| 08/24/2011 | EP2360186A1 Anti-P-selectin antibodies |
| 08/24/2011 | EP2360185A2 Administration of agents for the treatment of inflammation |
| 08/24/2011 | EP2360184A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/24/2011 | EP2360182A1 Therapeutic targeting of escort proteins |
| 08/24/2011 | EP2360177A1 Klebsiella antigens |
| 08/24/2011 | EP2360176A2 Hybrid and tandem expression of neisserial derived proteins |
| 08/24/2011 | EP2360175A2 Norovirus and Sapovirus virus-like particles (VLPs) |
| 08/24/2011 | EP2360174A1 HBV core antigen particles with multiple immunogenic components attached via peptide ligands |
| 08/24/2011 | EP2360173A1 Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof |
| 08/24/2011 | EP2360169A2 PSMA antibodies |
| 08/24/2011 | EP2360168A1 Flavivirus fusion inhibitors |
| 08/24/2011 | EP2359869A2 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same and uses therefor |
| 08/24/2011 | EP2359863A2 Isolation and use of solid tumor stem cells |
| 08/24/2011 | EP2359858A1 Nutritional composition comprising indigestible oligosaccharides |
| 08/24/2011 | EP2359857A2 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| 08/24/2011 | EP2359856A1 Formulation of human antibodies for treating TNF-alpha associated disorders |
| 08/24/2011 | EP2359855A2 Methods of administering anti-TNFalpha antibodies |
| 08/24/2011 | EP2359854A1 Pharmaceutical compositions and methods useful for modulating angiogenesis |
| 08/24/2011 | EP2359853A1 Pharmaceutical compositions and methods useful for modulating angiogenesis |
| 08/24/2011 | EP2359852A1 Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound |
| 08/24/2011 | EP2359851A2 MVA expressing modified hiv envelope, gag, and pol genes |
| 08/24/2011 | EP2359850A1 Single-time vaccines |
| 08/24/2011 | EP2359849A1 Combination therapy |
| 08/24/2011 | EP2359848A1 Peptide-based passive immunization therapy for treatment of atherosclerosis |
| 08/24/2011 | EP2359834A1 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| 08/24/2011 | EP2358756A1 High affinity human antibodies to pcsk9 |
| 08/24/2011 | EP2358755A1 c-MET ANTIBODIES |
| 08/24/2011 | EP2358753A1 Myostatin binding proteins |
| 08/24/2011 | EP2358739A1 Peptide conjugates for suppressing an immune response, methods of making and uses therefor |
| 08/24/2011 | EP2358733A2 Antigens that elicit immune response against flavivirus and methods of using same |
| 08/24/2011 | EP2358395A1 Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
| 08/24/2011 | EP2358394A1 Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
| 08/24/2011 | EP2358393A1 Therapeutic protein formulations |
| 08/24/2011 | EP2358392A1 Antibody formulation |
| 08/24/2011 | EP2358391A1 Use of an immunoglobulin g (igg) concentrate depleted of anti-a and anti-b antibodies for treating neonatal jaundice caused by maternal-foetal incompatibility with respect to the abo system |
| 08/24/2011 | EP2358390A1 Cd37 immunotherapeutic combination therapies and uses thereof |
| 08/24/2011 | EP2358389A1 Vaccines, which combine the antigen and toll-like receptors |
| 08/24/2011 | EP2358388A1 Pharmaceutical product for up-dosing of allergy vaccine |
| 08/24/2011 | EP2358387A1 Vaccine formulations and uses thereof |
| 08/24/2011 | EP2358386A2 Optimized influenza vaccines |
| 08/24/2011 | EP2358385A1 Agents and treatment for snoring and respiratory effort related arousals in sleep |
| 08/24/2011 | EP2358384A2 Salmonella marker vaccine |
| 08/24/2011 | EP2358383A1 Hiv/siv vaccines for the generation of mucosal and systemic immunity |
| 08/24/2011 | EP1934246B1 Matrix metalloproteinase 11 vaccine |
| 08/24/2011 | EP1856155B1 Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor |
| 08/24/2011 | EP1829887B1 Cpg single-strand deoxynucleotides for use as adjuvant |
| 08/24/2011 | EP1784487B1 Identification of cross-reactive epitopes of flavivirus envelope glycoprotein |
| 08/24/2011 | EP1644035B1 Ultrafiltration and ultracentrifugation for preparing outer membrane vesicles |
| 08/24/2011 | EP1545625B1 Flexible vaccine assembly and vaccine delivery platform |
| 08/24/2011 | EP1536006B1 Cancer antigens and utilization thereof |
| 08/24/2011 | EP1531843B1 Method for treating cervical cancer |
| 08/24/2011 | EP1499729B1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 08/24/2011 | EP1497320B1 New gene expressed in prostate cancer and methods of use |
| 08/24/2011 | EP1385540B1 Composition and method for increasing cell density in cell cultures infected with lentivirus |
| 08/24/2011 | EP1259544B1 Heterologous polypeptide of the tnf family |
| 08/24/2011 | EP1025121B1 Peptides capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor |
| 08/24/2011 | EP0981618B2 Anti-apo-2 antibody |
| 08/24/2011 | EP0754059B2 Methods and compositions useful for inhibition of angiogenesis |
| 08/24/2011 | CN102165075A Compositions for the detection and treatment of colorectal cancer |
| 08/24/2011 | CN102165064A The tuberculosis RV2386C protein, compositions and uses thereof |
| 08/24/2011 | CN102165062A New influenza virus immunizing epitope |
| 08/24/2011 | CN102165061A Modulation of TOLL-like receptor 9 expression by antisense oligonucleotides |
| 08/24/2011 | CN102164962A Anti-GD2 antibodies and methods and uses related thereto |
| 08/24/2011 | CN102164958A Humanization of rabbit antibodies using a universal antibody framework |
| 08/24/2011 | CN102164952A Novel compositions and methods |
| 08/24/2011 | CN102164613A Neutralizing anti-influenza a virus antibodies and uses thereof |
| 08/24/2011 | CN102164612A Novel compositions and methods |
| 08/24/2011 | CN102161982A Monoclonal antibodies (McAb) against human CXCR3 molecules and application thereof |
| 08/24/2011 | CN102161974A Preparation method and application of Vibro harveyi outer membrane protein (ompK) antigen as well as strain for expressing the same |
| 08/24/2011 | CN102160893A Taxus polysaccharide immunologic adjuvant and influenza vaccine containing same |
| 08/24/2011 | CN102160892A Epidemic encephalitis B and enterovirus 71 (EV71) combined vaccine |
| 08/24/2011 | CN102160856A Neglect-proof drinking immunization tablet for infectious bursal disease (IBD) and preparation method thereof |
| 08/24/2011 | CN101864399B Enterovirus and application thereof |
| 08/24/2011 | CN101628114B Broad spectrum anti-tumor composite vaccine |
| 08/24/2011 | CN101619306B Influenza B virus Vero cell productive adaptive strain and preparation and application thereof |
| 08/24/2011 | CN101550191B Malignant melanoma T cell nano antibody, coding sequence and application thereof |
| 08/24/2011 | CN101496899B Prevention, treatment and detection of progressive atrophic rhinitis of pig |
| 08/24/2011 | CN101220372B Recombined bifidobacteria -hRV/VP7 expression vector and oral vaccine thereof |
| 08/24/2011 | CN101220371B Recombined bifidobacteria hRV-VP4 expression vector and oral vaccine thereof |
| 08/24/2011 | CN101138633B BCG vaccine for preventing and reversing hypertrophy and fibrosis of cardiovascular organization |
| 08/24/2011 | CN101111521B Humanized antibody specific for tumor necrosis factor-alpha |
| 08/24/2011 | CN101098892B Antibodies against IL-13 receptor alpha 1 and uses thereof |
| 08/23/2011 | US8005623 Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity |
| 08/23/2011 | US8003776 Mycobacterial antigens expressed during latency |
| 08/23/2011 | US8003763 for in vitro diagnostics/antitumor agents; gene overexpression of cell surface proteins; bind Cripto and block the interaction between Cripto and activin-like kinase (ALK) 4 |
| 08/23/2011 | US8003758 BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells |
| 08/23/2011 | US8003688 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
| 08/23/2011 | US8003613 Methods and compositions for inducing apoptosis |
| 08/23/2011 | US8003608 Using small molecule amino acid derivatives |
| 08/23/2011 | US8003601 Pegylated mutated clostridium botulinum toxin |
| 08/23/2011 | US8003382 Nucleic acid molecules encoding a house dust mite allergen Der f VII, and antigenic peptides thereof |
| 08/23/2011 | US8003364 Purification of vaccinia viruses using hydrophobic interaction chromatography |